RISA Labs
Overview
RISA Labs is a healthtech startup focused on leveraging artificial intelligence to improve workflows in oncology care. Founded in 2024 by Kshitij Jaggi and Kumar Shivang, both IIT Kanpur alumni, RISA Labs is based in Palo Alto, California. Recently, the company has raised $3.5 million in seed funding led by Binny Bansal, co-founder of Flipkart, alongside other notable investors like Oncology Ventures, General Catalyst, and Ashish Gupta. Their flagship product, the Business Operating System as a Service (BOSS), is designed to streamline administrative processes in cancer care, enhancing efficiency and reducing delays in treatment caused by prior authorization bottlenecks.
Recent Developments
- April 2025: RISA Labs secured $3.5 million in a seed funding round to accelerate the deployment of its AI-based platform, BOSS, across 100 cancer centers in the United States over the next two years. This round was led by Binny Bansal, with participation from notable investors such as Oncology Ventures, General Catalyst, and more.
- The new funds will aid in the expansion of BOSS to combat inefficiencies in the oncology treatment process, specifically addressing delays caused by prior authorization requirements that affect 70% of cancer patients and potentially increase mortality risks.
- Already successfully implemented in a U.S. cancer center, BOSS has reduced prior authorization times significantly, from 30 minutes to under five, while processing over $1 million in medications and cutting administrative costs by 66%.
- RISA Labs aims to extend this platform beyond individual cancer treatment facilities to become a key player throughout the oncology ecosystem, partnering with life sciences organizations and healthcare providers.
- The company remains focused on enhancing coordination, efficiency, and intelligence across the oncology treatment life cycle.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2024 |
| Headquarters | Palo Alto, California |
| Founders | Kshitij Jaggi, Kumar Shivang |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | Binny Bansal, Oncology Ventures, General Catalyst, z21 Ventures, Odd Bird VC, Ashish Gupta |
| Industry | Healthtech |
| Number of Employees | 27 |
Early History
RISA Labs was founded in 2024 by Kshitij Jaggi and Kumar Shivang, both experienced entrepreneurs, having previously founded Urban Health, a healthcare startup focused on operational efficiency. The establishment of RISA Labs marked a pivot towards applying advanced AI solutions to streamline cumbersome administrative processes in cancer care, particularly the time-consuming prior authorization procedure. Their mission was to drastically reduce the delays in treatment initiation that cancer patients often face due to systemic inefficiencies. Recognizing that delays can be life-threatening, the founders were driven to create a platform that automates these processes with precision and speed.
Company Profile and Achievements
RISA Labs operates as a developer of artificial intelligence solutions aimed at automating complex data and workflow management, notably within the healthcare sector.
- Product & Services: Their flagship product, BOSS, serves as a comprehensive orchestration engine. This system disaggregates complex clinical workflows into micro-tasks managed by AI agents, ensuring seamless execution across various digital platforms within healthcare institutions.
- Achievements: In a short span after its launch, BOSS had significantly reduced administrative delays concerning prior authorizations by transforming a traditionally 30-minute process to one executed in under five minutes.
- Strategic Vision: RISA Labs embodies a long-term vision to become an AI transformation partner across the oncology domain, facilitating intelligent orchestration and enhancing cooperation among healthcare stakeholders.
Current Operations and Market Position
Currently, RISA Labs stands as a pioneering entity in automating health care workflows through AI. The company's BOSS platform is already making an impactful difference in reducing delays and administrative burdens in cancer treatment centers by:
- Increasing efficiency and reducing time spent on manual tasks
- Enhancing the accuracy and consistency of administrative workflows
- Aiding in potentially life-saving reductions in treatment delays, boosting the care quality for patients
Conclusion
RISA Labs is revolutionizing the way cancer care is delivered through AI-driven workflow automation. By consistently improving operational efficiencies across treatment centers in the U.S., they are not only enhancing patient care effectiveness but also saving critical resources within healthcare facilities. As they advance, their strategic focus will likely amplify their impact, potentially redefining treatment workflows across broader healthcare segments. With the ongoing support of investors and the recent funding injection, RISA Labs is well-positioned to become a pivotal player in the intersectional field of healthtech and artificial intelligence.